Diagnosing Health Care Podcast cover art

All Episodes

Diagnosing Health Care Podcast — 81 episodes

#
Title
1

DOJ's Bulk Sensitive Data Transfer Rule: Key Insights for Health Care Compliance Teams

2

The Down-Low on Data for Value-Based Enterprises and Their Participating Providers

3

42 CFR Part 2 Final Rule: What's Changing and What Do You Need to Know?

4

Current Tailwinds in Women's Health - What Do They Mean for Your Business?

5

Can Food Really Be Medicine? Transforming Health Care One Bite at a Time

6

Breaking Down the Shifting Vaccine Policy Landscape

7

Executive Actions Impact Federally Funded Research: What Institutions Should Do Now

8

Criminal Health Care Fraud Enforcement: Projections for 2025 and Beyond

9

2025 Outlook: The Department of Health and Human Services Under the Second Trump Administration

10

Health Policy Update: Impact of the 2024 U.S. Elections

11

Advancements of Artificial Intelligence in Health Care – One Year After White House Executive Order

12

Workplace Violence in Health Care: Dissecting the Legal Landscape and Implications for Employers

13

Navigating the Labyrinth of Private Equity Investments in Health Care

14

The DEA Is Knocking at Your Door . . . Are You Prepared?

15

The Future of Laboratory Testing Just Got a Little Clearer: FDA's Final Rule on LDTs

16

Down Goes Chevron: A 40-Year Precedent Overturned by the Supreme Court

17

Unveiling Gender-Affirming Care: Why It Matters and What's at Stake

18

Key Changes in Finalized Antitrust Merger Guidelines

19

Health Equity: Behind the Buzzwords

20

Telehealth Post-Public Health Emergency: What to Expect in 2024

21

Antitrust Updates: Changes Affecting Merger Review and Enforcement in 2024 and Beyond

22

Dietary Supplements: Navigating the Regulatory Maze

23

Direct Access Laboratory Testing: Future FDA Proposed Regulations on LDTs

24

Inflation Reduction Act's Drug Price Negotiation Provisions – What Now?

25

Post-Dobbs: One Year Later

26

Managing Trade Secrets and Restrictive Covenants in Health Care M&A Deals

27

The Legal Battle Over Mifepristone

28

Inflation Reduction Act's Drug Price Negotiation Provisions – What's Next?

29

Direct Access Laboratory Testing: Physician Orders and Specimen Collection

30

Legal and Regulatory Landscape for Psychedelics as Therapies

31

2023 Deal Cycle: Considerations for Transactions in Uncertain Economic Times

32

The End of the Public Health Emergency – What's to Come?

33

Direct Access Laboratory Testing: Reimbursement & Compliance

34

Direct Access Laboratory Testing: Navigating the Regulatory Landscape

35

Unpacking FDA's Final Clinical Decision Support Guidance

36

The PACE Program: What Changes May Be Coming Soon?

37

Post-Dobbs: Considerations for Clinical Trials and Research

38

2023 Health Policy Outlook

39

Post-Dobbs: Access to Reproductive Health Care and Abortion-Inducing Drugs

40

Post-Dobbs: Navigating the Fast-Changing and Uncertain Legal Landscape

41

Health Care's Past, Present, and Future

42

Hot Areas in COVID-19 Enforcement, Testing, and Funding

43

Interoperability: Information Blocking Claims and Enforcement

44

Impact of COVID-19 on Pharmacist Scope of Practice: Before and After the PREP Act

45

Interoperability: Health Care's Next Disruptor Is openEHR

46

Interoperability: A New Vision Through openEHR

47

OSHA's Permanent COVID-19 Standard and Enforcement Blitz

48

Entrepreneurship in Biotech: Growing Your Business

49

DOJ Goes After Civil Cyber-Fraud

50

Interoperability: The Role of Health Information Exchanges

51

Interoperability: The Provider Perspective

52

Chevron Deference: Is It Time for Change?

53

No Surprises Act: New Rules and Guidance for Stakeholders (Part 2)

54

No Surprises Act: New Rules and Guidance for Stakeholders (Part 1)

55

How Will Biden's Executive Order Impact Future Hospital Mergers?

56

What Is the Future of the Acute Care Hospital Industry?

57

Is the Dietary Supplement Regulatory Framework Working?

58

No Surprises Act: Considerations for Plans and Providers

59

How Can Companies in the Health Care and Life Sciences Industries Strengthen Their Cybersecurity Posture?

60

What's New for Insurers in Mental Health Parity Compliance

61

Federal and State Cannabis Rules Are Moving in Different Directions

62

Are Vaccine Passports the Key to Reopening?

63

Whistleblowing, Retaliation Risks Are On the Rise for Health Care Employers

64

CMS and OIG Final Rules for Innovating Your Value-Based Payment Program

65

American Rescue Plan Delivers New Stimulus Funding

66

President Biden's Use of the Defense Production Act

67

COVID-19 Vaccines: The Ethical and Legal Challenges to Immunization

68

Congressional Health Care Legislative Agenda

69

Private Equity Investment in Risk-Bearing Provider Organizations

70

The Biden Administration's First 100 Days

71

Forecast for Telehealth Fraud and Abuse Risk in 2021

72

Privacy Concerns When Contact Tracing in the Health Care Workplace

73

SCOTUS Watch: The ACA and Key Health Law Areas Justice Barrett Could Impact

74

On the Ballot 2020: Health Care Policy Outlook

75

Key Considerations for Reshoring U.S. Drug Manufacturing

76

Product Launching in the Era of COVID-19

77

Holding Pattern: Cannabis Industry Waits for FDA Regulatory Rulemaking

78

Fraud and Abuse Enforcement Priorities in the Wake of COVID-19

79

The Impact of Revenue and Budget Shortfalls in Light of Coronavirus

80

Telehealth Flexibility

81

Welcome to the Diagnosing Health Care Podcast